Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056271 · ClinicalTrials.gov registry record
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation
A clinical trial of Atrial Fibrillation, sponsored by Volta Medical.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT06056271 is a study of Atrial Fibrillation that is actively recruiting participants, run by Volta Medical. The registered enrollment target is 400 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06056271, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by Volta Medical.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.
Conditions Studied
Interventions
- DEVICE AF Ablation
Study Locations (4)
Illinois
- Endeavor Health - Evanston
Kansas
- Kansas City Cardiac Arrhythmia Research LLC - Overland Park
New York
- Northwell Health - New York
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06056271
The ClinicalTrials.gov registry entry for NCT06056271 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (87% lower). The listed sponsor is Volta Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which AF Ablation is the first listed.
NCT06056271 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT06056271 about?
NCT06056271 is a clinical study titled "Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation". Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.
What is the current status of trial NCT06056271?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-03-19. Estimated completion is 2027-12.
What conditions does trial NCT06056271 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT06056271?
The interventions under investigation include: AF Ablation (DEVICE).
Who is sponsoring clinical trial NCT06056271?
This trial is sponsored by Volta Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056271 being conducted?
This trial has 4 study locations across Illinois, Kansas, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.